Clinical Trial

A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is A multicenter, randomized, double-blind, placebo-controlled phase 2 clinical study to evaluate the efficacy and safety of HT-101 injection combined with HT-102 injection in patients with chronic hepatitis B. It consists of two phases: the main trial and the extension period. The main trial phase aims to explore the efficacy of different courses of HT-101 injection combined with HT-102 injection in treating patients with chronic hepatitis B and evaluate the optimal treatment strategy. The extension period phase, based on the main trial, assesses the long-term safety and efficacy of HT-101 injection combined with HT-102 injection.
Trial Details
NCT Number NCT07245953
Lead Sponsor Suzhou HepaThera Biotech Co., Ltd.
Conditions Chronic Hepatitis B
Enrollment 60 participants
Start Date 2025-11-05
Primary Completion 2027-02 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2025-11-24